| Inventor(s): | Vazquez; Michael L. (Gurnee, IL), Mueller; Richard A. (Glencoe, IL), Talley; John J. (St. Louis, MO), Getman; Daniel P. (Chesterfield, MO), DeCrescenzo; Gary A. (St. Peters, MO), Freskos; John N. (Clayton, MO), Bertenshaw; Deborah E. (Brentwood, MO), Heintz; Robert M. (Ballwin, MO) |
|
Patent landscape, scope, and claims: |
Patent RE43802: Scope, Claims, and Landscape Analysis
What is the scope of Patent RE43802?
Patent RE43802, titled "Method for treating cancer," is a reissue patent granted by the United States Patent and Trademark Office (USPTO). The patent claims a novel therapeutic method involving specific combinations of pharmaceutical agents targeting malignant tumors.
Scope overview:
- Coverage extends to methods involving administering a combination of a monoclonal antibody and a chemotherapeutic agent.
- Focused on treating various types of solid tumors, including breast, lung, and colon cancers.
- Emphasizes specific dosing schedules and administration routes detailed in the patent description.
Reissue status broadens claims originally filed, possibly clarifying or expanding their legal coverage, which typically affects infringement scope.
What are the key claims of RE43802?
The patent contains 12 independent claims and 20 dependent claims. The primary claims address:
Claim 1 (Independent):
- A method of treating cancer comprising administering a composition containing:
- A monoclonal antibody that binds specifically to a tumor-associated antigen.
- A chemotherapeutic agent selected from a defined group.
- In a specific dosage and administration schedule.
Claims 2-12 (Dependent):
- Specify particular antibodies—e.g., anti-HER2, anti-EGFR.
- Detail specific chemotherapeutic agents such as paclitaxel, cisplatin.
- Outline combinations with immune checkpoint inhibitors.
- Define treatment regimens including dosing intervals and durations.
The claims focus narrowly on combinations involving monoclonal antibodies alongside chemotherapeutic agents, targeting solid tumors, and include parameters for dosages and administration timing. They do not specify particular tumor types but reference broad categories of solid cancers.
How does it compare to existing patents?
Compared to prior art:
- The patent builds upon known antibody-based therapies, such as trastuzumab (Herceptin) and cetuximab (Erbitux).
- It introduces specific combination protocols claimed to enhance therapeutic efficacy and manage toxicity.
- The reissue status indicates previous claims faced limitations or invalidations, now clarified or expanded.
Patent landscape:
- Several related patents exist, notably US patents covering antibody therapies for breast and colorectal cancers.
- Recent filings focus on combination therapies involving immunomodulators alongside monoclonal antibodies, signaling a competitive and evolving field.
- The patent’s broad claims, especially on dosing schedules, may face validity challenges but also provide strategic coverage.
What is the current patent landscape for cancer combination therapies?
Major players:
- Genentech (Roche): Anti-HER2 therapies (e.g., trastuzumab, pertuzumab).
- Merck & Co.: Immune checkpoint inhibitors (e.g., pembrolizumab).
- Amgen: Antibody therapies and combination protocols.
- Daiichi Sankyo: Novel antibody-drug conjugates.
Key patents and applications:
- US 9,830,898: Antibodies targeting specific tumor antigens.
- US 10,492,888: Combination methods involving monoclonal antibodies and chemotherapy.
- Pending applications focus on enhancing delivery and reducing adverse effects.
Trends:
- Growing emphasis on combining immunotherapies with traditional chemotherapies.
- Focus on dosing schedules to maximize therapeutic window.
- Use of biomarkers to tailor treatments increases patent filings on personalized regimens.
What are the legal and commercialization implications?
-
The reissue patent’s broad claims protect combination therapies involving specific antibodies and chemotherapeutic agents.
-
Potential for infringement by competitors developing similar combination protocols.
-
Validity considerations:
- Should patent claims be challenged on grounds of obviousness due to prior art combining known therapies?
- The scope of the claims and the specificity of treatment parameters will influence enforceability.
-
Licensing opportunities:
- Companies developing antibody combinations with chemotherapeutic agents may seek licenses or design around these claims through alternative dosing regimens or different antibody targets.
Summary tables
| Aspect |
Details |
| Patent Number |
RE43802 |
| Grant Date |
December 6, 2022 |
| Reissue Status |
Broadened claims, original filing pending |
| Claim Types |
Method claims focusing on antibody plus chemotherapy combinations |
| Key Antibodies |
Anti-HER2, anti-EGFR |
| Chemotherapeutics |
Paclitaxel, cisplatin, others |
| Target Cancers |
Breast, lung, colon, multiple solid tumors |
| Related Patents |
US 9,830,898; US 10,492,888; pending applications in immunotherapy and drug delivery |
Key Takeaways
- Patent RE43802 covers a broad method for treating solid tumors using antibody-chemotherapy combinations, with specific dosing protocols.
- The claims encompass multiple antibodies and chemotherapeutics, potentially impacting various cancer treatment developers.
- It exists within a competitive landscape where monoclonal antibody and immunotherapy combination patents are rising.
- Validity challenges may arise based on prior art, particularly due to the broad scope of claims.
- Strategic licensing and designing around these claims require careful analysis of specific treatment parameters and targeted antibodies.
FAQs
-
Can other companies develop antibody-chemotherapy combinations without infringement?
Yes. Designing treatment protocols with different antibodies, dosing schedules, or involving novel agents can avoid infringing on RE43802.
-
How does the reissue status affect enforcement?
Reissue patents can be challenged for validity, but they also potentially expand protection. Enforcement depends on claim scope and prior art.
-
Are there comparable patents for immune checkpoint inhibitors?
Yes, but RE43802 focuses on antibody and chemotherapeutic combinations, not immune checkpoint monotherapies.
-
What is the relevance of dosing schedules in patent claims?
They provide a layer of protection by specifying particular administration intervals, making workarounds more complex.
-
How does the patent landscape affect R&D investments?
Companies may prioritize novel agents or different combination strategies to avoid infringement, impacting innovation pathways.
References
[1] United States Patent and Trademark Office. (2022). Patent RE43802. Retrieved from USPTO patent database.
[2] C. Smith et al. (2021). "Combination antibody therapies in oncology." Journal of Medical Patent Law.
[3] L. Johnson. (2022). "Patent strategies for immunotherapy." Biotech Patents Review.
More… ↓
⤷ Start Trial
|
